ReviewBrain sciences2025
A Unified Framework for Alzheimer's Disease Knowledge Graphs: Architectures, Principles, and Clinical Translation.
Review in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This review paper synthesizes the application of knowledge graphs (KGs) in Alzheimer's disease (AD) research, based on two basic questions, as follows: what types of input data are available to construct these knowledge graphs, and what purpose the knowledge graph is intended to fulfill. We synthesize results from existing works to illustrate how diverse knowledge graph structures behave in different data availability settings with distinct application targets in AD research. By comparative analysis, we define the best methodology practices by data type (literature, structured databases, neuroimaging, and clinical records) and application of interest (drug repurposing, disease classification, mechanism discovery, and clinical decision support). From this analysis, we recommend AD-KG 2.0, which is a new framework that coalesces best practices into a unifying architecture with well-defined decision pathways for implementation. Our key contributions are as follows: (1) a dynamic adaptation mechanism that adapts methodological elements automatically according to both data availability and application objectives, (2) a specialized semantic alignment layer that harmonizes terminologies across biological scales, and (3) a multi-constraint optimization approach for knowledge graph building. The framework accommodates a variety of applications, including drug repurposing, patient stratification for precision medicine, disease progression modeling, and clinical decision support. Our system, with a decision tree structured and pipeline layered architecture, offers research precise directions on how to use knowledge graphs in AD research by aligning methodological choice decisions with respective data availability and application goals. We provide precise component designs and adaptation processes that deliver optimal performance across varying research and clinical settings. We conclude by addressing implementation challenges and future directions for translating knowledge graph technologies from research tool to clinical use, with a specific focus on interpretability, workflow integration, and regulatory matters.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.